BMC Infectious Diseases, 2001 Background Pyrazinamide (PZA) is among the first-line drugs for the treatment of tuberculosis. In vitro, it kills semidormant mycobacteria only at low pH.
Kim Cheol Min +8 more
doaj +3 more sources
INSERSI GEN pncA KE DALAM PLASMID pGEM-T
Jurnal Kimia Riset, 2016 . Multidrug-resistant tuberculosis (MDR-TB) is among the most worrisome elements of the pandemic of antibiotic resistance. As the first line drug, pyrazinamide is often used to treat TB desease so there are many case of TB resistant to pyrazinamide. The
Eli Hendrik Sanjaya
doaj +3 more sources
Characteristics of
BMC Infectious Diseases, 2011 Background Pyrazinamide (PZA) is an important first-line drug in multidrug-resistant tuberculosis (MDRTB) treatment. However, the unreliable results obtained from traditional susceptibility testing limits its usefulness in clinical settings.
Lee Yu-Chin +5 more
doaj +3 more sources
Pyrazinamide Resistance and pncA Mutation Profiles in Multidrug Resistant Mycobacterium Tuberculosis
Infection and Drug Resistance, 2022 Dawei Shi,1,* Qiulong Zhou,2,* Sihong Xu,1 Yumei Zhu,3 Hui Li,4 Ye Xu2 1National Institutes for Food and Drug Control, Institute of Pathogen Biology at the Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People’s ...
Shi D, Zhou Q, Xu S, Zhu Y, Li H, Xu Y
doaj +3 more sources
Novel Mutations in pncA Gene of Pyrazinamide Resistant Clinical Isolates of Mycobacterium tuberculosis [PDF]
Scientia Pharmaceutica, 2018 In clinical isolates of Mycobacterium tuberculosis (MTB), resistance to pyrazinamide occurs by mutations in any positions of the pncA gene (NC_000962.3) especially in nucleotides 359 and 374.
Manijeh Kahbazi +6 more
doaj +3 more sources
Structure guided prediction of Pyrazinamide resistance mutations in pncA [PDF]
Scientific Reports, 2020 AbstractPyrazinamide plays an important role in tuberculosis treatment; however, its use is complicated by side-effects and challenges with reliable drug susceptibility testing. Resistance to pyrazinamide is largely driven by mutations in pyrazinamidase (pncA), responsible for drug activation, but genetic heterogeneity has hindered development of a ...
Karmakar, Malancha +4 more
openaire +6 more sources
Mechanisms of Antibiotic Resistance and Novel Therapeutic Approaches for <i>Mycobacterium tuberculosis</i>: A Narrative Review With a Focus on Tuberculosis Mutations in Iran. [PDF]
Health Sci RepABSTRACT Background and Aims Tuberculosis, caused by Mycobacterium tuberculosis (M. tuberculosis), is a highly contagious disease and one of the leading causes of mortality globally. The emergence and dissemination of multidrug‐resistant (MDR) strains of M. tuberculosis have become a major concern, especially in developing countries.
Bodaghi AB +5 more
europepmc +2 more sources
Comment on 'Systematic Review and Meta-Analysis of Protein Intake to Support Muscle Mass and Function in Healthy Adults' by Nunes et al.-The Authors' Reply. [PDF]
J Cachexia Sarcopenia MuscleJournal of Cachexia, Sarcopenia and Muscle, Volume 16, Issue 5, October 2025.
Nunes EA +6 more
europepmc +2 more sources
pncAMutations in the Specimens from Extrapulmonary Tuberculosis [PDF]
Tuberculosis and Respiratory Diseases, 2012 Pyrazinamide (PZA) is an effective antitubercular drug that becomes toxic to Mycobacterium tuberculosis when converted to pyrazinoic acid by pyrazinamidase (PZase), encoded by mycobacterial pncA. A strong association was noted between the loss of PZase activity and PZA resistance.
Jaechun Lee +7 more
openaire +2 more sources
Analysis of pncA gene expression in pyrazinamide-resistant and multidrug-resistant Mycobacterium tuberculosis [PDF]
Xin yixue, 2023 Objective To compare the expression levels of pncA gene in pyrazinamide （PZA）-resistant and multidrug-resistant Mycobacterium tuberculosis before and after PZA drug stimulation， and to explore the relationship between PZA-resistant Mycobacterium ...
Wang Nan，, Yang Yu, Deng Ling, Wu Hui, Liu Zhihui, Meng Fanrong
doaj +1 more source